StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Sunday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Brooklyn ImmunoTherapeutics stock opened at $6.29 on Friday. The stock has a 50-day simple moving average of $4.10 and a 200 day simple moving average of $1.91. The stock has a market capitalization of $370.02 million, a P/E ratio of -2.77 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $6.06 and a 52 week high of $8.31.

Brooklyn ImmunoTherapeutics Announces Dividend

The business also recently disclosed a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were given a $0.0862 dividend. This represents a $1.03 annualized dividend and a dividend yield of 16.44%. The ex-dividend date was Friday, March 14th. Brooklyn ImmunoTherapeutics’s payout ratio is presently -38.33%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.